Enliven Therapeutics
ELVN
31 hedge funds and large institutions have $18.8M invested in Enliven Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
43% more capital invested
Capital invested by funds: $13.1M → $18.8M (+$5.66M)
19% more funds holding
Funds holding: 26 → 31 (+5)
2.29% less ownership
Funds ownership: 10.12% → 7.83% (-2.3%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
66% less call options, than puts
Call options by funds: $939K | Put options by funds: $2.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$310K |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$251K |
| 3 |
JG
Jefferies Group
New York
|
+$154K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$146K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.23M |
| 2 |
LPC
Lion Point Capital
New York
|
-$1.14M |
| 3 |
Goldman Sachs
New York
|
-$1.06M |
| 4 |
Two Sigma Advisers
New York
|
-$223K |
| 5 |
Two Sigma Investments
New York
|
-$145K |
ELVN Hedge Fund Activity: Q3 2022 in Review
31 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2022, worth a combined $18.8M — up 43% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ELVN positions and 7 closed out — a net gain of 5 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was JBF Capital, opening a new position worth an estimated $310K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.23M sold.
- 31 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2022, up from 26 in Q2 2022.
- Funds reported $18.8M of Enliven Therapeutics stock for Q3 2022, up 43% quarter-over-quarter.
- 12 funds opened new Enliven Therapeutics positions in Q3 2022 and 7 closed out, a net change of +5 holders.
- The largest Enliven Therapeutics buyer in Q3 2022 was JBF Capital, an estimated $310K added.
- The largest Enliven Therapeutics seller in Q3 2022 was NEA Management Company, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2022.